Yüklüyor......
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
The identification of echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) fusion gene in non-small cell lung cancer (NSCLC) has radically changed the treatment of a subset of patients harboring this oncogenic driver. Crizotinib was the first ALK tyrosine kina...
Kaydedildi:
| Yayımlandı: | Drug Des Devel Ther |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5503498/ https://ncbi.nlm.nih.gov/pubmed/28740365 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S113500 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|